Ignite Creation Date:
2024-05-06 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06229548
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-29
First Post:
2023-12-20
Brief Title:
A Single Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of SYH2053
Sponsor:
CSPC Zhongnuo Pharmaceutical Shijiazhuang Co Ltd
Organization:
CSPC Zhongnuo Pharmaceutical Shijiazhuang Co Ltd
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of SYH2053 in Subjects With Normal or Elevated Low-Density Lipoprotein Cholesterol
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind placebo-controlled single ascending dose SAD study of SYH2053 when administered subcutaneously to subjects with normal and elevated LDL-C
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None